Eric Elenko

545 total citations
11 papers, 343 citations indexed

About

Eric Elenko is a scholar working on Pulmonary and Respiratory Medicine, Pharmaceutical Science and Immunology. According to data from OpenAlex, Eric Elenko has authored 11 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 2 papers in Pharmaceutical Science and 2 papers in Immunology. Recurrent topics in Eric Elenko's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Chemical Reactions and Isotopes (2 papers) and Glycogen Storage Diseases and Myoclonus (1 paper). Eric Elenko is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers), Chemical Reactions and Isotopes (2 papers) and Glycogen Storage Diseases and Myoclonus (1 paper). Eric Elenko collaborates with scholars based in United States, South Korea and Greece. Eric Elenko's co-authors include Daphne Zohar, Joseph C. Kvedar, Alexander L. Fogel, Kenneth M. Andrejko, Rebecca Taub, Drew E. Cressman, Rene E. Harrison, R Harrison, Clifford S. Deutschman and Barbara Haber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Biotechnology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Eric Elenko

9 papers receiving 330 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Elenko United States 7 92 61 50 37 34 11 343
Daphne Zohar United States 4 102 1.1× 64 1.0× 61 1.2× 37 1.0× 5 0.1× 4 289
Isabel Voigt Germany 12 119 1.3× 15 0.2× 59 1.2× 82 2.2× 9 0.3× 23 522
Andrea Gentili Italy 8 193 2.1× 62 1.0× 16 0.3× 106 2.9× 11 0.3× 19 483
Isabel Chien United States 11 72 0.8× 65 1.1× 16 0.3× 126 3.4× 17 0.5× 16 395
Bradley Patay United States 4 49 0.5× 53 0.9× 20 0.4× 46 1.2× 7 0.2× 10 492
Noah Zimmerman United States 8 60 0.7× 49 0.8× 21 0.4× 33 0.9× 6 0.2× 12 283
Eunyoung Heo South Korea 10 105 1.1× 36 0.6× 11 0.2× 40 1.1× 7 0.2× 15 313
Rachel A. Gladstone Canada 12 42 0.5× 13 0.2× 112 2.2× 21 0.6× 13 0.4× 16 842
Moom R. Roosan United States 13 51 0.6× 27 0.4× 6 0.1× 19 0.5× 14 0.4× 26 344
Scott MacDonald United States 10 83 0.9× 23 0.4× 11 0.2× 49 1.3× 6 0.2× 28 348

Countries citing papers authored by Eric Elenko

Since Specialization
Citations

This map shows the geographic impact of Eric Elenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Elenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Elenko more than expected).

Fields of papers citing papers by Eric Elenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Elenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Elenko. The network helps show where Eric Elenko may publish in the future.

Co-authorship network of co-authors of Eric Elenko

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Elenko. A scholar is included among the top collaborators of Eric Elenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Elenko. Eric Elenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Τzouvelekis, Αrgyris, Mark J. Hamblin, Won Il Choi, et al.. (2025). Late Breaking Abstract - ELEVATE IPF phase 2b open-label extension demonstrates durable efficacy of deupirfenidone. OA4456–OA4456.
2.
Maher, Toby M., Miguel Bergna, Amy Hajari Case, et al.. (2025). Deupirfenidone Compared to Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis: ELEVATE IPF Phase 2b Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A7046–A7046. 1 indexed citations
3.
4.
Chen, Michael C., et al.. (2021). A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium‐Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases. Clinical Pharmacology in Drug Development. 11(2). 220–234. 10 indexed citations
5.
Filipović, Aleksandra, Judy Wang, Johanna C. Bendell, et al.. (2021). 482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors. SHILAP Revista de lepidopterología. A512–A512. 6 indexed citations
6.
7.
Kvedar, Joseph C., Alexander L. Fogel, Eric Elenko, & Daphne Zohar. (2016). Digital medicine's march on chronic disease. Nature Biotechnology. 34(3). 239–246. 106 indexed citations
8.
Elenko, Eric, et al.. (2015). Defining digital medicine. Nature Biotechnology. 33(5). 456–461. 132 indexed citations
9.
Elenko, Eric, et al.. (2015). A regulatory framework emerges for digital medicine. Nature Biotechnology. 33(7). 697–702. 19 indexed citations
10.
Deutschman, Clifford S., Kenneth M. Andrejko, Barbara Haber, et al.. (1997). Sepsis-induced depression of rat glucose-6-phosphatase gene expression and activity. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 273(5). R1709–R1718. 27 indexed citations
11.
Andrejko, Kenneth M., et al.. (1996). Increased expression of cytokine-induced neutrophil chemoattractant in septic rat liver. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 271(3). R593–R600. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daphne Zohar Breakdown of academic impact, for papers by Isabel Voigt Breakdown of academic impact, for papers by Andrea Gentili Breakdown of academic impact, for papers by Isabel Chien Breakdown of academic impact, for papers by Bradley Patay Breakdown of academic impact, for papers by Noah Zimmerman Breakdown of academic impact, for papers by Eunyoung Heo Breakdown of academic impact, for papers by Rachel A. Gladstone Breakdown of academic impact, for papers by Moom R. Roosan Breakdown of academic impact, for papers by Scott MacDonald
Rankless by CCL
2026